Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Abiraterone Acetate in Healthy Chinese Volunteers
NCT04863105Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Plasma Concentration at Day 15, Area Under the Curve to Last Timepoint at Day 15 and 1 more. Started Nov 2017; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04863105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863105.